FY2024 EPS Estimate for Sage Therapeutics Lifted by Analyst

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Equities researchers at Wedbush raised their FY2024 earnings per share estimates for shares of Sage Therapeutics in a research note issued on Thursday, January 23rd. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will post earnings of ($7.01) per share for the year, up from their previous forecast of ($7.06). Wedbush has a “Neutral” rating and a $8.00 price objective on the stock. The consensus estimate for Sage Therapeutics’ current full-year earnings is ($6.47) per share. Wedbush also issued estimates for Sage Therapeutics’ Q4 2024 earnings at ($1.98) EPS, Q1 2025 earnings at ($1.24) EPS, Q2 2025 earnings at ($1.00) EPS, Q3 2025 earnings at ($0.95) EPS, Q4 2025 earnings at ($0.93) EPS, FY2025 earnings at ($4.11) EPS, FY2026 earnings at ($2.63) EPS, FY2027 earnings at ($0.36) EPS and FY2028 earnings at ($0.08) EPS.

A number of other research firms also recently weighed in on SAGE. Robert W. Baird dropped their price target on shares of Sage Therapeutics from $13.00 to $9.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 9th. StockNews.com lowered Sage Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. HC Wainwright reaffirmed a “neutral” rating and set a $14.00 price target on shares of Sage Therapeutics in a research note on Wednesday, November 20th. Stifel Nicolaus lowered their price target on Sage Therapeutics from $10.00 to $6.00 and set a “hold” rating for the company in a research note on Monday, December 16th. Finally, Bank of America dropped their price objective on Sage Therapeutics from $11.00 to $6.00 and set an “underperform” rating on the stock in a report on Wednesday, October 9th. Three equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $10.53.

Sage Therapeutics Stock Up 4.8 %

SAGE stock opened at $7.44 on Monday. The company has a 50 day moving average of $5.88 and a two-hundred day moving average of $7.28. The company has a market cap of $455.10 million, a price-to-earnings ratio of -1.33 and a beta of 0.91. Sage Therapeutics has a 12-month low of $4.62 and a 12-month high of $27.39.

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) EPS for the quarter, missing analysts’ consensus estimates of ($1.52) by ($0.01). The company had revenue of $11.87 million for the quarter, compared to analysts’ expectations of $10.80 million. Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. The business’s revenue for the quarter was up 337.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($2.81) earnings per share.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. RTW Investments LP boosted its holdings in Sage Therapeutics by 2.0% during the third quarter. RTW Investments LP now owns 5,591,700 shares of the biopharmaceutical company’s stock valued at $40,372,000 after acquiring an additional 111,123 shares during the period. State Street Corp lifted its position in shares of Sage Therapeutics by 18.2% during the 3rd quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company’s stock worth $21,127,000 after purchasing an additional 451,377 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Sage Therapeutics by 0.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company’s stock worth $8,975,000 after purchasing an additional 3,757 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Sage Therapeutics by 10.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 452,193 shares of the biopharmaceutical company’s stock valued at $3,265,000 after purchasing an additional 43,617 shares during the period. Finally, Squarepoint Ops LLC grew its holdings in Sage Therapeutics by 1,112.0% in the 2nd quarter. Squarepoint Ops LLC now owns 313,407 shares of the biopharmaceutical company’s stock valued at $3,404,000 after buying an additional 287,549 shares during the last quarter. Institutional investors own 99.22% of the company’s stock.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.